首页> 美国卫生研究院文献>European Journal of Rheumatology >Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: A case report
【2h】

Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: A case report

机译:托珠单抗成功治疗肿瘤坏死因子受体相关性周期性综合征(TRAPS):一例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is an autosomal dominant autoinflammatory disease linked to chromosome 12p13 and, more specifically, with mutations within the tumor necrosis factor receptor superfamily, member 1A gene (TNFRSF1A gene). It is characterized by the presence of fever, abdominal pain, myalgia, arthralgia or arthritis, and skin rash.In this report, we describe the case of a patient with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) treated successfully with the anti-interleukin-6 (anti-IL-6) receptor monoclonal antibody tocilizumab, while treatment with anti-TNF α etanercept and infliximab had both failed.
机译:肿瘤坏死因子受体相关周期性综合征(TRAPS)是一种常染色体显性遗传性自身炎性疾病,与染色体12p13相关,更具体地讲,是与肿瘤坏死因子受体超家族成员1A基因(TNFRSF1A基因)相关的突变。其特征是存在发烧,腹痛,肌痛,关节痛或关节炎和皮疹。在本报告中,我们描述了一种抗肿瘤药成功治疗的肿瘤坏死因子受体相关周期性综合征(TRAPS)患者的病例-interleukin-6(抗IL-6)受体单克隆抗体tocilizumab,而抗TNFαetanercept和英夫利昔单抗治疗均失败。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号